Assessment of lipid metabolism parameters in patients with ischemic chronic heart failure and concomitant metabolic pathology depending on nesfatinemia levels
DOI:
https://doi.org/10.14739/2310-1237.2025.3.334159Keywords:
chronic heart failure, coronary artery disease, type 2 diabetes mellitus, obesity, nesfatin-1, dyslipidemiaAbstract
The aim: to evaluate serum nesfatin-1 levels and their correlation with lipid profile parameters in patients with ischemic heart failure (HF) with and without concomitant metabolic comorbidities such as type 2 diabetes mellitus (T2DM) and obesity.
Materials and methods. The study included 225 patients with HF due to ischemic heart disease, divided into four groups: Group 1 (n = 75) – with T2DM and obesity; Group 2 (n = 50) – with T2DM; Group 3 (n = 50) – with obesity; Group 4 (n = 50) – without metabolic disturbances. Serum nesfatin-1 levels were determined using an enzyme-linked immunosorbent assay (ELISA). Biochemical analysis included measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very-low-density lipoprotein cholesterol (VLDL-C), as well as calculation of the atherogenic coefficient (AC). Correlation analysis was performed using Spearman’s rank correlation test.
Results. In patient groups with concomitant metabolic comorbidities (Groups 1, 2, and 3), statistically significant inverse correlations were observed between serum nesfatin-1 levels and pro-atherogenic lipids (TC, TG, LDL-C, VLDL-C), along with a significant direct correlation with the anti-atherogenic fraction (HDL-C). In these groups, higher nesfatin-1 levels were associated with a significant decrease in TC (17.6–24.6 %), TG (11.3–49.6 %), LDL-C (29.1–65.0 %), and AC (49.7–59.6 %), alongside an increase in HDL-C (23.1–44.7 %). In contrast, in Group 4 (patients without metabolic disturbances), the effect of nesfatin-1 on the lipid profile was less pronounced. While TG levels decreased significantly (by 28.6 %), other parameters (TC, HDL-C, LDL-C, AC) showed no statistically significant changes or only minimal variations. These findings suggest a context-dependent role of nesfatin-1 in lipid metabolism, with more pronounced effects in the presence of metabolic comorbidities.
Conclusions. Elevated serum nesfatin-1 levels are associated with an improved lipid profile in patients with ischemic HF complicated by type 2 diabetes mellitus and/or obesity, suggesting a potential protective role of this peptide in the presence of metabolic comorbidities. In contrast, in patients without metabolic disturbances, this effect is markedly attenuated or absent. These findings underscore the need for further investigation into the underlying mechanisms of nesfatin-1 action across different clinical populations.
References
Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. doi: https://doi.org/10.1016/j.cardfail.2022.02.010
Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi: https://doi.org/10.1161/CIR.0000000000000973
Bánfi-Bacsárdi F, Kazay Á, Gergely TG, Forrai Z, Füzesi TP, Hanuska LF, et al. Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act. J Clin Med. 2025;14(1):139. doi: https://doi.org/10.3390/jcm14010139
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi: https://doi.org/10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255. doi: https://doi.org/10.1093/eurheartj/ehz826
Tekin T, Cicek B, Konyaligil N. Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian J Med. 2019;51(3):280-4. doi: https://doi.org/10.5152/eurasianjmed.2019.18420
Luo JJ, Wen FJ, Qiu D, Wang SZ. Nesfatin-1 in lipid metabolism and lipid-related diseases. Clin Chim Acta. 2021;522:23-30. doi: https://doi.org/10.1016/j.cca.2021.08.005
Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front Physiol. 2020;11:578966. doi: https://doi.org/10.3389/fphys.2020.578966
Matta RA, El-Hini SH, Salama AM, Moaness HM. Serum nesfatin-1 is a biomarker of pre-diabetes and interplays with cardiovascular risk factors. Egypt J Intern Med. 2022;34:15. doi: https://doi.org/10.1186/s43162-022-00106-y
Chen X, Lv Y, Gao S, Li Y, An W, Zhang Y. Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway. Bioengineered. 2022;13(6):14670-81. doi: https://doi.org/10.1080/21655979.2022.2100860
Kuyumcu M, Al Bitar F, Yildiz A, Altiparmak IH. Nesfatin-1 Levels in Patients with Slow Coronary Flow. Biomed Res Int. 2018;2018:2519183. doi: https://doi.org/10.1155/2018/2519183
Angelone T, Rocca C, Pasqua T. Nesfatin-1 in cardiovascular orchestration: From bench to bedside. Pharmacol Res. 2020;156:104766. doi: https://doi.org/10.1016/j.phrs.2020.104766
Karvane HB, Esfandiari H, Qutaiba O, Allela B, Mahdi MS, Al-Nuaimi AM, et al. Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1. BMC Endocr Disord. 2024;24(1):257. doi: https://doi.org/10.1186/s12902-024-01791-2
Kadoglou NP, Korakas E, Lampropoulos S, Maratou E, Kassimis G, Patsourakos N, et al. Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study. Cardiovasc Diabetol. 2021;20(1):166. doi: https://doi.org/10.1186/s12933-021-01355-x
Nguyen MT, Pham VA, Nguyen QD, Tran DM, Nguyen QP, Tran TT, et al. A cross-sectional study on the Nesfatin-1 serum levels of Vietnamese patients with pre-diabetes. Rev Assoc Med Bras (1992). 2023;69(5):e20221388. doi: https://doi.org/10.1590/1806-9282.20221388
Yanar F, Tokat B, Bugra Z, Oztürk O, Yilmaz Aydogan H. Rs214101 Variation of NUCB2/Nesfatin-1 Gene: Effects on Metabolic Parameters Independent of Type 2 Diabetes or Obesity in Coronary Artery Disease. J Hum Genet Genomics.2018;2(1):e80059. doi: https://doi.org/10.5812/jhgg.80059
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 K. M. Borovyk, O. I. Kadykova, P. H. Kravchun, V. D. Babadzhan, N. H. Ryndina, A. O. Sypalo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
